Hanyang Med Rev.  2012 Aug;32(3):145-153. 10.7599/hmr.2012.32.3.145.

Treatment Strategy for Parkinsonian Diseases Through Mesenchymal Stem Cells

  • 1Department of Neurology and Brain Research Institute, Yonsei University College of Medicine, Severance Biomedical Science Institute, Yonsei University, Seoul, Korea. phisland@chol.net


Parkinsonian diseases including Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases representative of alpha-synucleinopathies characterized pathologically by alpha-synuclein-abundant Lewy bodies and glial cytoplasmic inclusions, respectively. Cell therapy using mesenchymal stem cells (MSCs) is attractive clinically because these cells are free from ethical and immunological problems. MSCs are present in adult bone marrow and represent <0.01% of all nucleated bone marrow cells. MSCs are multipotent, and differentiation under appropriate conditions into chondrocytes, skeletal myocytes, and neurons has been demonstrated thus far. According to recent studies, the neuroprotective effect of MSCs is mediated by the production of various trophic factors that contribute to functional recovery, neuronal cell survival, and endogenous regeneration of neural tissues. Additionally, MSCs appear to have immunoregulatory properties that can ameliorate the progression of disease. However, the therapeutic use of MSCs as neuroprotectives in PD and MSA has seldom been studied. Here we comprehensively review recent advances in clinical strategies using MSCs in PD and MSA, especially focusing on their neuroprotective properties in preventing or delaying disease progression and therapeutic potential for providing functional recovery.


Mesenchymal Stem Cells; Therapeutics; Parkinsonian Disorders

MeSH Terms

Bone Marrow
Bone Marrow Cells
Cell Survival
Disease Progression
Inclusion Bodies
Lewy Bodies
Mesenchymal Stromal Cells
Multiple System Atrophy
Muscle Fibers, Skeletal
Neurodegenerative Diseases
Neuroprotective Agents
Parkinson Disease
Parkinsonian Disorders
Tissue Therapy
Neuroprotective Agents
Full Text Links
  • HMR
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error